Market Cap | 5.54M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -5.4M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -11.00% |
Sales | 150.16k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -30.00% |
Dividend | N/A | Price/Book | 1.17 | EPS next 5Y | - | 52W High Chg | -76.00% |
Recommedations | - | Quick Ratio | 4.06 | Shares Outstanding | 10.59M | 52W Low Chg | 17.00% |
Insider Own | 21.17% | ROA | -118.92% | Shares Float | 7.91M | Beta | 5.71 |
Inst Own | 2.61% | ROE | -202.23% | Shares Shorted/Prior | 37.37K/16.46K | Price | 0.76 |
Gross Margin | 82.95% | Profit Margin | - | Avg. Volume | 22,108 | Target Price | - |
Oper. Margin | -4,832.42% | Earnings Date | - | Volume | 2,235 | Change | 0.28% |
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
White Mark | President/CEO President/CEO | Sep 15 | Buy | 4.15 | 25,000 | 103,750 | 309,127 | 06/30/23 |
Kazden Alan | Director Director | Sep 16 | Buy | 4.15 | 2,500 | 10,375 | 83,131 | 06/30/23 |
Elson Marilyn | Ms. Elson serves as.. Ms. Elson serves as CFO | Sep 28 | Buy | 1.12 | 9,500 | 10,640 | 835,244 | 09/29/22 |
White Mark | President/CEO President/CEO | Sep 15 | Buy | 4.15 | 25,000 | 103,750 | 289,627 | 09/22/22 |